Oramed Pharmaceuticals EBITDA 2011-2024 | ORMP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Oramed Pharmaceuticals ebitda from 2011 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Oramed Pharmaceuticals ebitda from 2011 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$205.5B
Stryker (SYK)	$138.7B
Boston Scientific (BSX)	$121.5B
Medtronic (MDT)	$113.7B
EssilorLuxottica (ESLOY)	$104.2B
Haleon (HLN)	$48.6B
Lonza Group Ag (LZAGY)	$45.9B
ResMed (RMD)	$36.9B
Koninklijke Philips (PHG)	$29.3B
Terumo (TRUMY)	$27.8B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$20.3B
Insulet (PODD)	$16.5B
Smith & Nephew SNATS (SNN)	$13.5B
Bio-Rad Laboratories (BIO)	$9.3B
Demant (WILYY)	$9.2B
BellRing Brands (BRBR)	$7.7B
Lantheus Holdings (LNTH)	$7.3B
ICU Medical (ICUI)	$4.3B
Haemonetics (HAE)	$3.9B
TG Therapeutics (TGTX)	$3.9B
GN Store Nord (GNNDY)	$3.8B
Perrigo (PRGO)	$3.8B
Neogen (NEOG)	$3.7B
Prestige Consumer Healthcare (PBH)	$3.6B
Envista Holdings (NVST)	$3.3B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Maravai LifeSciences Holdings (MRVI)	$2.3B
Green Thumb Industries (GTBIF)	$2.2B